Madleen Orumaa

Background

Madleen Orumaa started as a research assistant at the Cancer Registry in 2014, defended her PhD in 2020, and has been employed as a postdoc in the Section for Molecular Epidemiology and Infections since 2022. She previously worked as a postdoctoral researcher at the National Institute for Health Development in Tallinn, Estonia. Madleen's research is related to overarching HPV topics, including vaccines, testing, and screening.

 

Madleen Orumaa works as a post doc in the Seksjon for molekylær epidemiologi og infeksjoner and is involved with several projects that are studying epidemiology of HPV-related diseases (mainly cervical cancer) and HPV vaccine impact in population against cervical abnormalities.

Madleen Orumaa has a master’s degree from the University of Tartu, Estonia (2014) after which she started to work as a research assistant at the KRG. In 2016, she was employed as a PhD student and in 2020 September she successfully defended her PhD thesis called “Time trends of selected HPV-related diseases in Norway and the impact of HPV multi-cohort vaccination using real-world data from population-based registries” at the University of Oslo. From 2020 to 2022, she worked as a post-doc at the National Institute for Health Development in Tallinn, Estonia where she led a project called “Assessment of Pap-smear quality and adherence to clinical guidelines in the follow-up of abnormal findings among cervical cancer patients in Estonia”. Since August 2022 she has returned to KRG to continue to work research HPV-related diseases and HPV vaccine impact.     

Nygård S, Nygård M, Orumaa M, Hansen BT. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals. Vaccine. 2023 Aug 23;41(37):5469-5476. doi: 10.1016/j.vaccine.2023.07.031. Epub 2023 Jul 27. Erratum in: Vaccine. 2023 Aug 26;: PMID: 37516572.

Orumaa M, Innos K, Suurna M, Salumäe L, Veerus P. Quality Assessment of Cervical Cytology Practices in Estonia From 2007 to 2018. Cancer Control. 2022 Jan-Dec;29:10732748221141794. doi: 10.1177/10732748221141794. PMID: 36542780; PMCID: PMC9793007.

Orumaa M, Campbell S, Støer NC, Castle PE, Sen S, Tropé A, Adedimeji A, Nygård M. Impact of the Mobile Game FightHPV on Cervical Cancer Screening Attendance: Retrospective Cohort Study. JMIR Serious Games. 2022 Dec 13;10(4):e36197. doi: 10.2196/36197. PMID: 36512401; PMCID: PMC9795393.

Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020 Feb 5;38(6):1345-1351. doi: 10.1016/j.vaccine.2019.12.016. Epub 2020 Jan 6. PMID: 31917039.

Orumaa M, Leinonen MK, Campbell S, Møller B, Myklebust TÅ, Nygård M. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. Int J Cancer. 2019 Nov 15;145(10):2629-2638. doi: 10.1002/ijc.32195. Epub 2019 Mar 4. PMID: 30734284; PMCID: PMC6767573.